Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
OBJECTIVE
To report the protocol for surveillance of the eye and vision in a clinical trial of MART1-transduced dendritic cells for metastatic melanoma.


METHODS
In a phase I/II clinical trial of dendritic cell-based genetic immunotherapy for metastatic cutaneous melanoma, ophthalmic evaluation is performed prior to immunization (Baseline Evaluation), 56+/-7 days after first vaccination (mid-study evaluation), when dendritic cell injections are complete 112+/-7 days after first vaccination (end-study evaluation) and 168+/-7 days after first vaccination (post-study evaluation).


RESULTS
The protocol for baseline, mid-study and end-study evaluations of the eye and vision includes ophthalmic history, comprehensive ophthalmic examination, psychophysical and electrophysiological visual function assessment, fundus photography and fluorescein angiography. Post-study evaluation consists of the 25-item visual functioning questionnaire augmented to elicit autoimmune manifestation with complete ophthalmic evaluation if vision-related symptoms or abnormalities are noted during or after the vaccination.


CONCLUSIONS
Limited adverse effects on the eye and vision have been reported in melanoma immunotherapy trials, although this novel mode of therapy has the potential to induce melanoma paraneoplastic syndromes known to severely impair vision. Therefore, surveillance of the eye and vision should be considered in melanoma immunotherapy trials.
Gordon
Lynn K
LK
Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA.
Ribas
Antoni
A
Nusinowitz
Steven
S
Butterfield
Lisa H
LH
Glaspy
John A
JA
Economou
James S
JS
Straatsma
Bradley R
BR
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000276:immunology*; D002986:Clinical Trials as Topic; D015350:Contrast Sensitivity; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation*; D004306:Dose-Response Relationship, Immunologic; D004596:Electroretinography / Q000379:methods; D005128:Eye Diseases / Q000175:diagnosis*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007271:Injections, Intradermal; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics* / Q000276:immunology*; D011159:Population Surveillance / Q000379:methods*; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy*; D014161:Transduction, Genetic / Q000379:methods; D014611:Vaccination / Q000379:methods; D014786:Vision Disorders / Q000175:diagnosis*; D014792:Visual Acuity / Q000502:physiology; D014794:Visual Fields / Q000502:physiology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins